No Data
No Data
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Eli Lilly And Company (LLY): Among Stocks to Buy That May Be Splitting Soon
Trump Administration Follows Biden in Defending 340B Drug-discount Program
Sector Update: Health Care Stocks Edge Down in Afternoon Trading
Eli Lilly (NYSE:LLY) Welcomes Circular Genomics To Gateway Labs For Advancing Alzheimer's Biomarker Research
Is Eli Lilly and Company (LLY) the Best Diabetes Stock to Buy According to Billionaires?
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E